middle.news

Bioxyne Posts Record $21.3m Quarterly Revenue, Secures Aurora Manufacturing Deal

8:56am on Tuesday 21st of April, 2026 AEST Pharmaceuticals
Read Story

Bioxyne Posts Record $21.3m Quarterly Revenue, Secures Aurora Manufacturing Deal

8:56am on Tuesday 21st of April, 2026 AEST
Key Points
  • Record $21.3m quarterly revenue, up 137% year-on-year
  • Manufacturing deal signed with Aurora Cannabis for medicinal cannabis oils and vapes
  • Initial purchase orders secured for GMP psilocybin capsules for treatment-resistant depression
  • Positive operating cash flow of $1.2m despite working capital investment
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Bioxyne (ASX:BXN)
OPEN ARTICLE